Severity
Moderate
FDA Devices recall · Reported April 11, 2018
The stability specifications of ImmunoCAP Allergen c5, Ampicilloyl were not met.
Phadia US Inc recalled ImmunoCAP Allergen c5, Ampicilloyl (article number 14-4450-01). ImmunoCAP Specific IgE… - a moderate-severity action.
ImmunoCAP Allergen c5, Ampicilloyl (article number 14-4450-01). ImmunoCAP Specific IgE… was recalled by Phadia US Inc in April 11, 2018. Reason: The stability specifications of ImmunoCAP Allergen c5, Ampicilloyl were not met.. Check the official notice for the remedy. Verify recall #Z-1312-2018 with the FDA Devices before acting.
The recall
Phadia US Inc issued this moderate-severity FDA Devices recall-The stability specifications of ImmunoCAP Allergen c5, Ampicilloyl were not met..
Sourced from official FDA Devices enforcement records. Verify recall #Z-1312-2018 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Devices action (record #Z-1312-2018) was formally reported on April 11, 2018, with the manufacturer initiating the action on December 18, 2017. It is classified under Moderate severity (Class II), with a current status of Terminated. Phadia US Inc is listed as the recalling firm, operating out of Portage, MI. Federal records list the affected scope as 950 total.
The documented reason for this recall is: The stability specifications of ImmunoCAP Allergen c5, Ampicilloyl were not met. Distribution data in the federal record shows the product reached: Nationwide Distribution. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 3 from FDA Devices - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 40,322 medical devices recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
950 total
Related Recalls
6
3 from same agency
ImmunoCAP Allergen c5, Ampicilloyl (article number 14-4450-01). ImmunoCAP Specific IgE is an in vitro quantitative assay for the measurement of allergen specific IgE in human serum or plasma. To be used with the instrument Phadia 250, Phadia 1000, Phadia 2500 and Phadia 5000.
The stability specifications of ImmunoCAP Allergen c5, Ampicilloyl were not met.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | Z-1312-2018 |
| Date reported | April 11, 2018 |
| Date initiated | December 18, 2017 |
| Recalling firm | Phadia US Inc |
| Firm location | Portage, MI |
| Affected scope | 950 total |
| Distribution | Nationwide Distribution |
Profile values are sourced directly from the official FDA Devices enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Devices record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
· 2026-07-02
· 2026-06-25
· 2026-06-18
GE Medical Systems Information Technologies Inc · 2026-06-03
Medline Industries, LP · 2026-06-03
Compare this recall with Rowenta Recalls Cordless Vacuum Cleaners Due to Risk of Ser… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Devices, reported April 11, 2018. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.